Modulight as an investment
Modulight Corporation is a biomedical company that designs and manufactures laser devices for the treatment of cancer and eye diseases and for genetics. The company also manufactures products for other high-value applications such as quantum computing.
In January 2023, Modulight Corporation received the PMA (premarket approval) from the U.S. Food and Drug Administration (FDA) for its ML6710i laser device for the treatment of wet age-related macular degeneration (AMD) in the United States.
In 2022, Modulight’s revenue was EUR 4.6 million. The company’s EBITDA in 2022 was EUR -5.9 million and the EBITDA margin was -129.1 percent.
Modulight's customers use the company's comprehensive laser product solutions in the pharmaceutical and biomedical treatments and products they offer, where laser technology brings significant added value. Modulight’s customers include in total more than ten international pharmaceutical companies and Fortune 500 listed companies as well as several well-known cancer research institutes and universities in the United States, Japan and Europe.
Modulight has over 20 years of experience in medical applications, the development and manufacture of lasers and optics. Since 2014, the company’s main focus has been on providing laser solutions for the medicine and biomedicine sectors. More specifically, Modulight has been involved in developing various laser-based treatment methods for indications within oncology and ophthalmology.
Modulight's laser solutions are also used in other products where laser technology brings significant added value, often related to improved functionality, performance or manufacturability of the customer's own product or service. Modulight seeks growth, particularly in the United States. Other target markets are Europe and Asia. The company’s products are exported to all continents.
Expert in lasers and optics
years of experience in medical applications, the development and manufacture of lasers and optics
in total more than ten international pharmaceutical companies and Fortune 500 listed companies as customers
projects ongoing at the end of 2022, share of large multinational companies grew